{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"This outcome measure was included in error as the time point was before ramucirumab (IMC-1211B) was administered. Cmin was not analyzed.","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"}],"populationDescription":"Zero participants were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1 predose (28-day cycles)","title":"Minimum Concentration (Cmin) Prior to First Ramucirumab (IMC-1211B) Infusion","type":"SECONDARY"}